Full Breakdown
EU Sets Safe Consumption Level for Cannabidiol (CBD)
2/10/2026, 7:24:17 PM
Introduction of Safe Consumption Guidelines
On February 9, 2023, the European Food Safety Authority (EFSA) announced its first-ever safe consumption level for cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant. This decision establishes a provisional intake limit that is notably lower than those set by other countries, including Britain and Switzerland. CBD is commonly infused in various food and drink products such as sweets, honey, biscuits, cakes, tea, and coffee, and is recognized for its potential therapeutic benefits, including anxiety reduction, pain relief, and anti-inflammatory properties.
Provisional Safe Intake Levels
EFSA's panel of experts determined a provisional safe intake level of 0.0275 milligrams per kilogram of body weight per day, equating to approximately 2 mg daily for a 70-kg adult. This guideline contrasts sharply with the higher limits established in other nations: Britain allows up to 10 mg per day, Switzerland permits 12 mg, and Canada has a range of 20-200 mg per day for a maximum of 30 days, contingent upon consultation with a pharmacist regarding other medications.
Rationale Behind the Guidelines
The EFSA's cautious approach stems from uncertainties surrounding the long-term effects of CBD consumption. The agency highlighted potential risks related to liver function, neurological health, and impacts on reproductive and immune systems. Consequently, the EFSA's assessment specifically excluded individuals under 25 years of age, pregnant or breastfeeding women, and those on medication. The authority indicated that these safe consumption levels could be revised as new scientific data emerges.
Criticism and Opposition
Some stakeholders have expressed concern regarding the EFSA's conservative stance. Critics argue that the low consumption limit may hinder the growth of the CBD market in Europe, which is already lagging behind other regions. They advocate for a more balanced approach that considers existing research on CBD's safety and efficacy, suggesting that the limits should be aligned more closely with those of other countries to foster industry development.
Official Statements
In its announcement, EFSA emphasized the need for ongoing research, stating, "Uncertainties remain regarding the kinetic behaviour and the effects of long-term consumption of CBD." The agency's commitment to reassessing safe consumption levels as new data becomes available reflects its cautious approach to public health.
What's Next
As the CBD market continues to evolve, further studies and data collection will be essential in shaping future regulations. Stakeholders in the industry are likely to advocate for adjustments to the current guidelines to better align with international standards, potentially influencing future EFSA assessments.
